| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Deflazacort-d3 does not have a direct biological target, as it is an analytical standard. However, its non-deuterated parent compound, Deflazacort, targets the glucocorticoid receptor. Deflazacort is an inactive prodrug that is rapidly converted in vivo to its active metabolite, 21-desacetyldeflazacort. This active metabolite binds to the glucocorticoid receptor, a nuclear receptor that regulates gene transcription. Upon binding, the receptor-ligand complex translocates to the nucleus and modulates the expression of various genes involved in inflammatory and immune responses. This leads to the anti-inflammatory and immunosuppressive effects for which Deflazacort is used clinically.
|
|---|---|
| ln Vitro |
In vitro, Deflazacort-d3 is not evaluated for pharmacological activity, as it is an internal standard. Its primary in vitro application is in the development and validation of LC-MS/MS methods for the quantification of Deflazacort and its metabolites. The compound's performance is assessed by its ability to co-elute with the analyte, its isotopic purity, and its lack of interference in the mass spectrometric detection. It is used to correct for matrix effects and ion suppression during sample preparation and analysis.
|
| ln Vivo |
In vivo, Deflazacort-d3 is not used as a therapeutic agent. It is an analytical standard used to quantify the concentration of the parent drug and its active metabolite in biological samples, such as patient plasma, collected from in vivo studies or clinical trials. The validated use of Deflazacort-d3 in patient plasma supports bioequivalence studies and therapeutic drug monitoring.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assay protocols are not applicable to Deflazacort-d3, as it is an analytical standard. Instead, it is used in analytical protocols, particularly in LC-MS/MS methods. A standard protocol involves adding a known amount of the deuterated internal standard to a biological sample (e.g., plasma, tissue homogenate). This is followed by protein precipitation or solid-phase extraction to isolate the analytes. The extract is then injected into an LC-MS/MS system, where the analytes are separated chromatographically and detected by mass spectrometry. The ratio of the analyte peak area to the internal standard peak area is used for quantification.
|
| Cell Assay |
In vitro cell-based assay protocols are not applicable to Deflazacort-d3. Its use is limited to analytical chemistry applications for the quantification of Deflazacort and its metabolites.
|
| Animal Protocol |
In vivo animal experimental protocols are not applicable to Deflazacort-d3, as it is an internal standard and not a pharmacologically active compound for in vivo studies.
|
| ADME/Pharmacokinetics |
Deflazacort-d3 is a stable isotope-labeled internal standard for LC-MS/MS quantification of Deflazacort and its active metabolite. It has a molecular weight of 444.54. It is not a therapeutic agent and has no clinical applications. Its mechanism of action is not applicable, as it is used as an analytical standard. The compound is available for research purposes.
|
| References | |
| Additional Infomation |
Deflazacort-d3 is a research-grade stable isotope-labeled compound used as an internal standard for the quantification of Deflazacort, a glucocorticoid prodrug, and its active metabolite 21-desacetyldeflazacort. Deflazacort is FDA-approved for Duchenne muscular dystrophy (DMD). Deflazacort-d3 is not a drug and has no therapeutic applications. It is used in analytical method development and validation, as well as in bioequivalence and pharmacokinetic studies. The compound is available for research purposes.
|
| Exact Mass |
444.234
|
|---|---|
| CAS # |
2280940-17-0
|
| PubChem CID |
76973185
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
32
|
| Complexity |
996
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
[2H]C([2H])([2H])C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)OC(=N2)C
|
| InChi Key |
FBHSPRKOSMHSIF-YJDMYKBNSA-N
|
| InChi Code |
InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1/i2D3
|
| Chemical Name |
[2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] 2,2,2-trideuterioacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
